Recent Updates
Recently added Catalysts
TRAX Positive Sentiment

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

Key Takeaway: First Tracks Biotherapeutics, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences. The events include the Wells Fargo Healthcare Conference, Citi's Biopharma Back to School Conference, and the Morgan Stanley Global Healthcare Conference. The executive team will engage in fireside chats and one-on-one meetings, providing investors with insights into the company's developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple prestigious investor conferences
  • Opportunity for one-on-one meetings with investors
  • Live webcast available for broader audience engagement

Full Press Release Details

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:

21 st Annual Wells Fargo Healthcare Conference, Boston

• Format – Fireside chat and one-on-one investor meetings
• Date and Time – Wednesday, Sept. 9, 2026 at 9:30am ET / 6:30am PT

Citi's 2026 Biopharma Back to School Conference, New York City

• Format – One-on-one investor meetings
• Date and Time – Thursday, Sept. 10, 2026

Morgan Stanley 24th Annual Global Healthcare Conference, New York City

• Format – One-on-one investor meetings
• Date and Time – Wednesday, Sept. 16, 2026
A live webcast of the fireside chat will be available on the investor section of the First Tracks website at https://ir.firsttracksbio.com/news-events/events. A replay of the webcast will be available for at least 30 days following the event.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.

Investor Contact: Nick Montemarano Vice President, Investor Relations 858.732.0178 investors@firsttracksbio.com

Frequently Asked Questions

What conferences will First Tracks Biotherapeutics attend?

First Tracks Biotherapeutics will attend the Wells Fargo Healthcare Conference, Citi's Biopharma Back to School Conference, and the Morgan Stanley Global Healthcare Conference.

When is the Wells Fargo Healthcare Conference?

The Wells Fargo Healthcare Conference is scheduled for September 9, 2026, at 9:30am ET.

Will there be a webcast of the events?

Yes, a live webcast of the fireside chat will be available on the First Tracks website.

What is the focus of First Tracks Biotherapeutics?

First Tracks Biotherapeutics focuses on advancing antibody therapeutics for autoimmune and inflammatory diseases.

Last updated: Aug 26, 2026